磷脂酰乙醇胺介导的代谢膜重塑在肥胖相关阿尔茨海默病中的作用
Phosphatidylethanolamine-mediated metabolic membrane remodeling in obesity-associated Alzheimer's disease: mechanisms, neuroimmune crosstalk, and therapeutic potential.
一句话摘要
综述肥胖相关磷脂酰乙醇胺(PE)代谢重塑如何经膜动力学、线粒体稳态、自噬、氧化应激与神经免疫交互影响阿尔茨海默病进展;作者提出「代谢膜重塑轴」作为整合框架,并指出脂质组结果异质、动物模型依赖度高,转化解释受限。
为什么重要
在淀粉样蛋白假说临床受挫的背景下,提出以脂质代谢与膜重塑为切入点理解肥胖与 AD 的关联,属于机制框架的拓展尝试。
英文摘要原文
Alzheimer's disease is increasingly recognized as a multifactorial neurodegenerative disorder characterized by complex interactions among metabolic dysfunction, chronic inflammation, mitochondrial impairment, and lipid dysregulation. Although the amyloid cascade hypothesis has long dominated Alzheimer's disease research, limited clinical success of amyloid-targeted therapies has highlighted the need for broader mechanistic frameworks integrating systemic metabolic and cellular dysfunction. Emerging evidence suggests that obesity-associated phospholipid remodeling, particularly dysregulation of phosphatidylethanolamine (PE), may critically influence neurodegenerative progression through alterations in membrane dynamics, mitochondrial homeostasis, autophagy, oxidative stress, and neuroimmune signaling. This review critically examines the molecular and cellular mechanisms underlying PE-mediated adipose-brain crosstalk in obesity-associated Alzheimer's disease, with emphasis on mitochondrial dysfunction, blood-brain barrier disruption, ferroptosis, membrane remodeling, and microglial activation. The review further discusses how altered PE metabolism may impair synaptic integrity, promote lipotoxicity, and enhance neuronal vulnerability under chronic metabolic stress. Current evidence, however, remains constrained by methodological heterogeneity, inconsistent lipidomic findings, and substantial reliance on experimental animal models, limiting translational interpretation. In addition, this review proposes the concept of a "metabolic membrane remodeling axis" as an integrative framework linking obesity-driven phospholipid dysregulation with neuroimmune and neurodegenerative progression. A deeper understanding of PE-driven neuroimmunometabolic dysfunction may facilitate biomarker discovery and support the development of lipid-targeted therapeutic strategies for obesity-associated Alzheimer's disease.
所属章节
条目编号 P114 · 元数据经 Crossref / Europe PMC 回查